pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, C
LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Cellular Matrix / A-CP-HA Kit
Approved · small molecule · Genitourinary Syndrome of Menopause
Cellular Matrix / A-CP-HA Kit for Genitourinary Syndrome of Menopause is a Approved program (small_molecule) at Regeneron Ireland Designated Activity Company (DAC) with 1 ClinicalTrials.gov record(s).
Internal code FSD-CEL-2023-11
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron Ireland Designated Activity Company (DAC)
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Genitourinary Syndrome of Menopause
- Status
- active
- Trials
- 1